Flourish Research的动态

Accurate. Comprehensive. Actionable #HeartFlow

5th publication from the ALPHEUS trial , that brings us insight on predictors and best management of PCI in chronic coronary syndrome. Bravo to the newest member of the fantastic Pitié-Salpêtière team @ stéphane manzo-silberman that led this analysis with the help of the ACTION Coeur group . More analysis to come, stay tuned. Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome | JACC: Cardiovascular Interventions https://lnkd.in/ewRYywq9

This week's #QuickTakes with Julia Colombijn highlights the systematic underrepresentation of CKD patients in cardiovascular clinical trials. Watch the full video explaining the findings here: https://lnkd.in/g2HxUWdj

Vasolabs, Inc. highlights the importance of Carotid Intima-Media Thickness (CIMT) measurements in assessing cardiovascular health. Learn how this non-invasive technique helps detect early signs of atherosclerosis and guides proactive treatment plans. Check out our CIMT poster and see how we're making strides in cardiovascular diagnostics! #vasolabs #CIMT #CardiovascularHealth #PreventiveCare #MedicalInnovation

?? The B3 study reveals groundbreaking benefits of Closed Loop Stimulation (CLS) in patients with Sinus Node Disease (SND) and indicated for dual-chamber pacing! ?? Did you know that CLS significantly delays subclinical AF, reducing the risk of stroke and other cardiac complications? Dr. Ennio C. L. Pisanò shared insights from the multicenter, prospective B3 study, showing the superiority of CLS versus accelerometer-based rate adaptive pacing. Key Findings: ? CLS reduces subclinical AF and stroke risk by 16% compared to conventional accelerometer-based pacing. ? CLS delays new onset of AHREs, especially those of long duration. ? SND patients with preserved AV conduction and no AF history benefit most from CLS pacing. ? CLS is a unique impedance-based myocardial contractility sensor that proves to delay the onset of Subclinical AF in patients wiht Sinus Node Disease (SND) and indicated for dual-chamber pacing. Find out more: https://ow.ly/Y9uR50RcSoE #CardiacRhythm #SinusNodeDisease #SubclinicalAF #RateAdaptive #ClosedLoopStimulation

BLVR impact on cardiac function: A single-center, non-randomized, prospective study showed significant clinical improvements in cardiac preload, myocardial contractility and cardiac output for patients with severe #COPD/#emphysema without a history of cardiovascular disease.* Read more: https://bit.ly/3ESBsTD #BLVR #Bronchoscopy #MedDevice #Pulmonology

A great meeting with Caroline Bravo discussing the recent developments in device therapy as rhythm management. Assessment of arrhythmogenic risk in non-ischaemic cardiomyopathy, increasing age of cardiovascular patients, non-cardiac comorbidity, the armentarium of devices and which device for which patient, the increasing role of conduction system pacing, etc. How to educate the community to increase awareness..Boston Scientific #EPeeps #ICD #CIED #arrhythmias

Veradigm has one of the largest real world data sets comprised of 53 million de-identified patients. Some interesting findings from the recent Veradigm Cardiovascular Conditions in 2024 report: 1. CVD is the leading cause of death globally accounting for 1 in every 5 deaths in the U.S. and 1 in every 3 deaths worldwide. 2. Between 2018 and 2019 the US spent $240B on medical services, medication, and loss of productivity due to cardiovascular disease. 3. Out of the 53 million patients that had a BMI higher than 30, 46% have high cholesterol and 50% have hypertension. 4. The South (southern states in the US) has the highest prevalence of hypertension, coronary heart diseases, and heart failure. 5. Heart disease is more common in men, non-Hispanic and White communities (compared to women and Asian and Hispanic communities) Time to go for a run! #americanheartmonth

BLVR impact on cardiac function: A single-center, non-randomized, prospective study showed significant clinical improvements in cardiac preload, myocardial contractility and cardiac output for patients with severe #COPD/#emphysema without a history of cardiovascular disease.* Read more: https://bit.ly/3ESBsTD #BLVR #Bronchoscopy #MedDevice #Pulmonology

Patients with a small annulus in the aortic valve of the heart – the ring-like base of the valve that supports its leaflets – face challenges when undergoing transcatheter aortic valve replacement (TAVR). These patients, many of them women, are at greater risk for a host of poor outcomes. Now, the?largest, randomized, controlled TAVR trial to primarily enroll women has some answers to address this.?Results of the SMART trial, comparing self-expanding and balloon-expandable TAVR valves in patients with a small annulus, were recently published in the?New England Journal of Medicine, with UH Harrington Heart & Vascular Institute’s?Guilherme Attizzani, MD,?Interventional Director of?the Valve and Structural Heart Disease Center, as study co-author and steering committee member. Dr. Attizzani also holds the Alexander and Marianna McAfee Endowed Chair in Innovative Cardiovascular Intervention. SMART trial results show advantages for the self-expanding valve – already in regular use at UH for patients with a small annulus. But Dr. Attizzani says the study is likely to have wide impact elsewhere and cause clinicians?who haven’t typically used these devices to take a second look. Read more at https://lnkd.in/gzz42n9v #TAVR #SMARTtrial #womenshealth #hearthealth #physicianexcellence #patientsfirst